Key result
Prophylactic ACEi delays the onset of DMD-related dilated cardiomyopathy.
Why the study?
Because of the lack of DMD-specific drugs, current management for established DCM relies on standard heart failure treatments.
Early recognition and prophylactic use of ACE inhibitors, along with standard heart failure therapies, are the mainstay strategies for managing Duchenne muscular dystrophy cardiomyopathy.
Supports guideline-directed prophylactic ACE inhibitor use in DMD; leaves open need for randomized confirmation.
Duchenne muscular dystrophy (DMD) cardiomyopathy (DCM) is characterized by a hypokinetic, dilated phenotype progressively increasing with age. Regular cardiac care is crucial in DMD care. Early recognition and prophylactic use of angiotensin converting enzyme inhibitors (ACEi) are the main stay therapeutic strategy to delay incidence of DMD-DCM. Pharmacological treatment to improve symptoms and left ventricle (LV) systolic function, have been widely implemented in the past years. Because of lack of DMD specific drugs, actual indications for established DCM include current treatment for heart failure (HF). This review focuses on current HF strategies to identify, characterize, and treat DMD-DCM.
No takes yet. Share an insight, caveat, or question.
Adorisio et al. (2020) studied this question. Prophylactic use of ACE inhibitors is crucial for delaying the onset of DMD-related dilated cardiomyopathy in affected patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: